News & Updates

Type 2 hepatitis no different from type 1 in terms of outcome

02 May 2023

Liver outcomes do not differ between types 1 and 2 autoimmune hepatitis presenting in childhood, reports a recent study.

Type 2 hepatitis no different from type 1 in terms of outcome

02 May 2023

Intake of unsaturated fat, protein provides benefits on liver fat, metabolism in adults

26 Apr 2023

Adherence to a diet rich in protein and unsaturated fatty acids (UFAs) helps improve liver fat and lipid metabolism in people at risk of unhealthy ageing, a recent study has shown.

Intake of unsaturated fat, protein provides benefits on liver fat, metabolism in adults

26 Apr 2023

Adverse events occur in two-thirds of NASH patients on placebo

24 Apr 2023

Nearly two in three participants in the placebo arm of nonalcoholic steatohepatitis (NASH) randomized clinical trials (RCTs) experience an adverse event (AE), while one in 10 have a serious AE, according to a pooled analysis of studies with NASH placebo.

Adverse events occur in two-thirds of NASH patients on placebo

24 Apr 2023

More movement tied to lower risks of hospitalization for common health conditions

18 Apr 2023 by

Individuals engaging in more physical activities had lower risks of hospitalization for a multitude of common health conditions, according to a prospective cohort study using data from the UK Biobank.

More movement tied to lower risks of hospitalization for common health conditions

18 Apr 2023

ARO-HSD well tolerated in NASH patients

02 Apr 2023

An RNA interference therapy, ARO-HSD, is tolerable at ≤200-mg doses, suggests a phase I/II study. Short-term treatment with ARO-HSD results in decreases in hepatic HSD17β13 mRNA and protein expression, which is complemented by alanine aminotransferase reductions.

ARO-HSD well tolerated in NASH patients

02 Apr 2023

Tumour immune barrier determines immunotherapy efficacy in HCC

01 Apr 2023

A tumour immune barrier (TIB) structure formed by the interaction of SPP1+ macrophages and cancer-associated fibroblasts (CAFs) appears to influence the efficacy of immunotherapy in patients with hepatocellular carcinoma (HCC), reveals a study.

Tumour immune barrier determines immunotherapy efficacy in HCC

01 Apr 2023

Oral HBV cccDNA inhibitor a promising cure against chronic HBV infection

31 Mar 2023

A recent study has found a small-molecule covalently closed circular DNA (cccDNA) inhibitor that reduces levels of hepatitis B virus (HBV) cccDNA. This discovery offers a new way to cure patients with chronic HBV infection.

Oral HBV cccDNA inhibitor a promising cure against chronic HBV infection

31 Mar 2023

Tenofovir disoproxil fumarate as good as entecavir for patients with HBV-related liver cancer

30 Mar 2023

Treatment with tenofovir disoproxil fumarate (TDF) yields similar rates of recurrence and overall survival as does entecavir in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), according to a study.

Tenofovir disoproxil fumarate as good as entecavir for patients with HBV-related liver cancer

30 Mar 2023

Time-restricted eating offers no additional benefits in adults with obesity, NAFLD

24 Mar 2023

Time-restricted eating does not appear to be more effective than daily calorie restriction in terms of improving intrahepatic triglyceride content, body fat, and metabolic risk factors for adults with obesity and nonalcoholic fatty liver disease (NAFLD), according to a study.

Time-restricted eating offers no additional benefits in adults with obesity, NAFLD

24 Mar 2023

HCC risk in CHB patients persists 12 years after HBsAg loss

21 Mar 2023 by

Patients with chronic hepatitis B (CHB) still have a non-negligible risk of hepatocellular carcinoma (HCC) 12 years after achieving hepatitis B surface antigen (HBsAg) seroclearance, especially if cirrhosis is present, a large territory-wide real-world study in Hong Kong has shown.

HCC risk in CHB patients persists 12 years after HBsAg loss

21 Mar 2023

News & Updates

Filter by Specialty:

Specialty:

Type 2 hepatitis no different from type 1 in terms of outcome

Type 2 hepatitis no different from type 1 in terms of outcome

Intake of unsaturated fat, protein provides benefits on liver fat, metabolism in adults

Intake of unsaturated fat, protein provides benefits on liver fat, metabolism in adults

Adverse events occur in two-thirds of NASH patients on placebo

Adverse events occur in two-thirds of NASH patients on placebo

More movement tied to lower risks of hospitalization for common health conditions

More movement tied to lower risks of hospitalization for common health conditions

ARO-HSD well tolerated in NASH patients

ARO-HSD well tolerated in NASH patients

Tumour immune barrier determines immunotherapy efficacy in HCC

Tumour immune barrier determines immunotherapy efficacy in HCC

Oral HBV cccDNA inhibitor a promising cure against chronic HBV infection

Oral HBV cccDNA inhibitor a promising cure against chronic HBV infection

Tenofovir disoproxil fumarate as good as entecavir for patients with HBV-related liver cancer

Tenofovir disoproxil fumarate as good as entecavir for patients with HBV-related liver cancer

Time-restricted eating offers no additional benefits in adults with obesity, NAFLD

Time-restricted eating offers no additional benefits in adults with obesity, NAFLD

HCC risk in CHB patients persists 12 years after HBsAg loss

HCC risk in CHB patients persists 12 years after HBsAg loss